Cdc meningitis vaccine information sheet

Cdc meningitis vaccine information sheet

Vaccine Information Statement, Pneumococcal Conjugate fact sheet Keywords: Vaccine Information Statement, What you need to know fact sheet, Pneumococcal Conjugate fact sheet, Pneumococcal Conjugate vaccine, Pneumococcal Conjugate vaccination, Pneumococcal Conjugate vaccine fact sheet, pcv13, prevnar 13, pcv13 fact sheet, pcv13 v Created Date Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B; The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed

Is there a vaccine to prevent meningococcal meningitis? There are two types of meningococcal vaccines available in the US: • Meningococcal polysaccharide vaccine (MPSV4)- marketed under the trade name Menomune. • Meningococcal conjugate vaccine (MCV4) - produced by different companies under the names Menactra and Menveo.

Meningitis B is a potentially fatal disease that can affect anyone. Learn more facts about how meningitis B spreads, the symptoms, and the risk factors. Prescribing Information | For US Healthcare Professionals INDICATION. Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age Meningococcal Disease . What is meningococcal disease? Meningococcal disease is caused by bacteria called Neisseria meningitidis. It can lead to serious blood infections. When the linings of the brain and spinal cord become infected, it is called meningitis. The disease strikes quickly and can have serious complications, including death.

Anyone can get Meningococcal disease, but it is more common in infants and children. College students as a group are at lower risk of Meningococcal infection than young adults who are not in college. However, for some students, such as freshmen living in dormitories, there is an increased risk of ... INDICATION. Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age

Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B; The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed vaccine, or if you have a severe allergy to any part of this vaccine, you should not get the vaccine. Tell your health care provider if you . have . any severe allergies that you know of, including a severe allergy to latex. He or she can tell you about the vaccine’s ingredients. • If you are pregnant or breastfeeding. Anyone can get Meningococcal disease, but it is more common in infants and children. College students as a group are at lower risk of Meningococcal infection than young adults who are not in college. However, for some students, such as freshmen living in dormitories, there is an increased risk of ...

Meningitis B is a potentially fatal disease that can affect anyone. Learn more facts about how meningitis B spreads, the symptoms, and the risk factors. Prescribing Information | For US Healthcare Professionals

INDICATION. Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age Meningococcal Disease . What is meningococcal disease? Meningococcal disease is caused by bacteria called Neisseria meningitidis. It can lead to serious blood infections. When the linings of the brain and spinal cord become infected, it is called meningitis. The disease strikes quickly and can have serious complications, including death. • Covering of the brain (meningitis). Pneumococcal pneumonia kills -about 1 out of 20 people who get it. Bacteremia kills about 1 person in 5, and meningitis about 3 -people in 10. People with the health problems described in Section 3 of this statement may be more likely to die from the disease. drug. 2 Pneumococcal polysaccharide vaccine ... INDICATION. Trumenba is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. Trumenba is approved for use in individuals 10 through 25 years of age Code of Maryland Regulations became effective on November 12, 2001. See link below. To aid in complying with the law, a sample information sheet on the risks associated with meningococcal disease and the availability and effectiveness of the vaccine is provided on this site, as well as a sample waiver form.

Vaccine Information Statements (VIS) are information sheets produced by the Centers for Disease Control and Prevention (CDC) that explain to vaccine recipients, their parents, or their legal representatives both the benefits and risks of a vaccine. Anyone can get Meningococcal disease, but it is more common in infants and children. College students as a group are at lower risk of Meningococcal infection than young adults who are not in college. However, for some students, such as freshmen living in dormitories, there is an increased risk of ...

Vaccine Information Statements (VISs) are information sheets produced by the CDC that explain both the benefits and risks of a vaccine to vaccine recipients. Federal law requires that healthcare staff provide a VIS to a patient, parent, or legal representative before each dose of certain vaccines.

Trumenba is a vaccine indicated for individuals 10 through 25 years of age for active immunization to prevent invasive disease caused by Neisseria meningitidis group B; The effectiveness of the two-dose schedule of Trumenba against diverse N meningitidis group B strains has not been confirmed

Vaccine Information Statements (VIS) are information sheets produced by the Centers for Disease Control and Prevention (CDC) that explain to vaccine recipients, their parents, or their legal representatives both the benefits and risks of a vaccine. This information sheet discusses the bacille Calmette-Guerin (BCG) vaccine for TB disease, which is used in many countries to prevent childhood tuberculous meningitis and miliary disease. Links with this icon indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website. Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.

Vaccine Information Statement: Meningococcal ACWY Vaccine: What You Need to Know Author: CDC/NCIRD Keywords: Meningococcal, meningococcal vaccine, meningococcal vaccination, MCV4, menACWY, quadrivalent meningococcal vaccine, meningococcal vaccine fact sheet, Vaccine Information Statement, meningococcal fact sheet, meningococcal conjugate vaccine Is there a vaccine to prevent meningococcal meningitis? There are two types of meningococcal vaccines available in the US: • Meningococcal polysaccharide vaccine (MPSV4)- marketed under the trade name Menomune. • Meningococcal conjugate vaccine (MCV4) - produced by different companies under the names Menactra and Menveo.